Table 2.
T-cell subset frequencies in diabetic patients and NGT subjects.
| NGT (n=218) | T2D (n=95) | LADA (n=82) | T1D (n=81) | |
|---|---|---|---|---|
| CD4+ T | 40.40 (34.20, 46.60) | 43.40 (36.40, 51.50)** | 41.00 (32.10, 49.40) | 44.20 (38.35, 50.70) |
| IFN-γ+CD4+ T | 14.8 (10.37, 21.82) | 14.2 (9.03, 20.1) | 11.7 (9.11, 20.95)* | 9.5 9.55 (6.51, 14.75) ** |
| Th2 | 2.09 (1.34, 2.97) | 2.34 (1.39, 3.48) | 1.2 (0.73, 2.40) *† | 1.65 (1.02, 2.36) |
| Th17 | 1.08 (0.75, 1.54) | 1.27 (0.82, 2.01) * | 1.15 (0.73, 2.17) | 0.98 (0.72, 1.44) |
| IFN-γ+CD8+ T | 42.5 (30.30, 59.00) | 39.5 (22.80, 55.07) | 41.2 (23.30, 60.80)* | 22.7 (13.40, 32.80) *** |
| Treg | 2.67 (1.71, 3.85) | 2.97 (2.16, 4.13) | 2.81 (1.90, 3.98) | 2.62 (1.80, 3.65) |
| CD4+ Naïve T | 41.64 (31.41,52.15) | 39.41 (23.99,54.98) | 34.10 (21.89,47.77) | 52.29 (40.50,62.08) |
| CD4+ Tcm | 11.50 (7.96,17.04) | 14.45 (8.65,21.47) | 16.97 (12.26,21.40) ** | 12.24 (8.91, 18.40) |
| CD4+ Teff | 2.76 (1.35, 5.31) | 2.34 (1.09, 4.42) | 2.21 (0.82, 3.98)* | 1.39 (0.76, 2.78)** |
| CD4+ Tem | 6.83 (3.33, 10.86) | 12.85 (6.89,20.15)*** | 10.40 (6.55,13.83)**††† | 6.11 (2.46, 9.36) †††‡‡ |
| CD8+ T | 21.70 (17.00, 27.10) | 20.60 (16.25, 26.80) | 21.50 (15.15, 27.65) | 24.00 (15.50, 29.35) |
| CD8+ Naïve T | 38.14 (20.39, 51.11) | 18.85 (10.43, 35.65) | 25.51 (9.42, 47.63) | 53.11 (37.04, 66.66) |
| CD8+ Tcm | 2.80 (1.92, 3.88) | 4.28 (2.18, 6.67)*** | 3.65 (2.00, 6.05) | 1.91 (1.19, 3.29)†† |
| CD8+ Teff | 7.83 (4.29, 16.07) | 13.84 (7.36, 22.66) | 7.28 (3.97, 14.42) | 5.08 (2.54, 10.60) |
| CD8+ Tem | 10.31 (6.04, 15.38) | 19.49 (10.04,28.45)*** | 14.68 (9.22, 23.53) † | 8.28 (4.96, 13.24)†††‡ |
Compared with NGT * p<0.05, **p<0.01,*** p<0.001. Compared with T2D †p<0.05, ††p<0.01, †††p<0.001. Compared with LADA ‡p<0.05, ‡‡p<0.01. Data are expressed as the median values (25th-75th percentiles) and compared by the Kruskal-Wallis test. LADA, patients with latent autoimmune diabetes in adults; NGT, normal glucose tolerance subjects; T1D, type 1 diabetic subjects; T2D, type 2 diabetic subjects.